WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors against programmed death-1 (PD-1)/PD-1 ligand (PD-L1) have shown significant efficacy in various solid cancers, but their activity against TNBCs remains limited. Here, we report that human TNBCs molecularly stratified for high levels of PD-L1 (PD-L1 High ) showed significantly enriched expression of immune and cancer stemness pathways compared with those with low PD-L1 expression (PD-L1 Low ). In addition, the PD-L1 High cases were significantly associated with a high stemness score (SS High ) signature. TNBC cell lines gated for aldehyde dehydrogenase (ALDH) and CD44 stemness markers exhibited increased levels of PD-L1 versus their ALDH-negative and CD44 Low counterparts, and PD-L1 High cells generated significantly more mammospheres than PD-L1 Low cells. Murine mammary SCA-1-positive tumor cells with PD-L1 High expression generated tumors in vivo with higher efficacy than PD-L1 Low cells. Furthermore, treatment of TNBC cells with selective WNT inhibitors or activators downregulated or upregulated PD-L1 expression, respectively, implying a functional cross-talk between WNT activity and PD-L1 expression. Remarkably, human TNBC samples contained tumor elements co-expressing PD-L1 with ALDH1A1 and/or CD44v6. Additionally, both PD-L1-/SCA1-positive and ALDH1A1-positive tumor elements were found in close contact with CD3-, and PD-1-positive T cells in murine and human tumor samples. Overall, our study suggests that PD-L1-positive tumor elements with a stemness phenotype may participate in the complex dynamics of TNBC-related immune evasion, which might be targeted through WNT signaling inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activating mutations in the Wnt/β-catenin pathway can also induce resistance to ICB through altering the expression of PD-L1 and PD-L2 in a broad group of tumors such as melanoma, breast cancer, adenoid cystic carcinoma, and medulloblastoma (Bockmayr et al., 2018; Castagnoli et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Castagnoli et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 4×
“The bar plot shows the significant top enrichment scores (−log p value). b GSEA enrichment plots of Jak-stat signaling, T cell receptor signaling, and negative regulation of WNT gene sets in PD-L1High compared with PD-L1Low TNBC cases.”
ResultInfluentialGene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Hu, Y., & Smyth, G. K. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.008 · Cited by 2,083
AmiGO: online access to ontology and annotation data
Carbon, S., Ireland, A., Mungall, C. J., Shu, S., Marshall, B., Lewis, S., Hub, T. A., & the Web Presence Working Group (2009) · Bioinformatics · doi:10.1093/bioinformatics/btn615 · Cited by 1,952
Jordan, C. T., Guzman, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,702
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 851
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 602
Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome
Khramtsov, A. I., Khramtsova, G. F., Tretiakova, M., Huo, D., Olopade, O. I., & Goss, K. H. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091125 · Cited by 509
Liu, S., Lachapelle, J., Leung, S., Gao, D., Foulkes, W. D., & Nielsen, T. O. (2012) · Breast Cancer Research · doi:10.1186/bcr3148 · Cited by 436
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Hsu, J.-M., Xia, W., Hsu, Y.-H., Chan, L.-C., Yu, W.-H., Cha, J.-H., Chen, C.-T., Liao, H.-W., Kuo, C.-W., Khoo, K.-H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04313-6 · Cited by 434 · cited 1×
“These data are consistent with our results and establish the WNTsignaling pathway as the main mechanism upregulating PDL1 expression in the TNBCSC compartment [48].”
ResultGeyer, F. C., Lacroix-Triki, M., Savage, K., Arnedos, M., Lambros, M. B., MacKay, A., Natrajan, R., & Reis-Filho, J. S. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.205 · Cited by 373
Subtyping of triple‐negative breast cancer: Implications for therapy
Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2015) · Cancer · doi:10.1002/cncr.28914 · Cited by 333
Jang, G.-B., Kim, J.-Y., Cho, S.-D., Park, K.-S., Jung, J.-Y., Lee, H.-Y., Hong, I.-S., & Nam, J.-S. (2015) · Scientific Reports · doi:10.1038/srep12465 · Cited by 328 · cited 1×
“In light of these studies and the evidence that silencing WNT reduces the MFE of breast CSCs in vitro [44], and taking into consideration the relevant need to increase cancer cell immunogenicity, we herein evaluated the potential to “knock-down” PD-L1 expression on CSCs by modulating the activity of its regulatory sig…”
BackgroundBiomarkers of response to PD-1/PD-L1 inhibition
Maleki Vareki, S., Garrigós, C., & Duran, I. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.001 · Cited by 318 · cited 2×
“therapy response in different cancer populations, the identification of solid predictors is an urgent and challenging clinical need, to optimize treatment selection [16].”
BackgroundWnt signaling in triple-negative breast cancer
Pohl, S.-G., Brook, N., Agostino, M., Arfuso, F., Kumar, A. P., & Dharmarajan, A. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.14 · Cited by 296
Alsuliman, A., Colak, D., Al-Harazi, O., Fitwi, H., Tulbah, A., Al-Tweigeri, T., Al-Alwan, M., & Ghebeh, H. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0421-2 · Cited by 285
Mohammed, M. K., Shao, C., Wang, J., Wei, Q., Wang, X., Collier, Z., Tang, S., Liu, H., Zhang, F., Huang, J., et al. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2015.12.004 · Cited by 259
Wnt signaling in triple negative breast cancer is associated with metastasis
Dey, N., Barwick, B. G., Moreno, C. S., Ordanic-Kodani, M., Chen, Z., Oprea-Ilies, G., Tang, W., Catzavelos, C., Kerstann, K. F., Sledge, G. W., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-537 · Cited by 255
Almozyan, S., Colak, D., Mansour, F., Alaiya, A., Al‐Harazi, O., Qattan, A., Al‐Mohanna, F., Al‐Alwan, M., & Ghebeh, H. (2017) · International Journal of Cancer · doi:10.1002/ijc.30834 · Cited by 238
Lee, Y., Shin, J. H., Longmire, M., Wang, H., Kohrt, H. E., Chang, H. Y., & Sunwoo, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2665 · Cited by 219
Emens, L. A., Braiteh, F. S., Cassier, P., Delord, J.-P., Eder, J. P., Fasso, M., Xiao, Y., Wang, Y., Molinero, L., Chen, D. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2859 · Cited by 211
β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells
Xu, J., Prosperi, J. R., Choudhury, N., Olopade, O. I., & Goss, K. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117097 · Cited by 180
Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?
Bruttel, V. S., & Wischhusen, J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00360 · Cited by 174
Targeting the WNT Signaling Pathway in Cancer Therapeutics
Tai, D., Wells, K., Arcaroli, J., Vanderbilt, C., Aisner, D. L., Messersmith, W. A., & Lieu, C. H. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0057 · Cited by 159 · cited 2×
“related scenario that could potentially be reverted through the use of WNT inhibitors, which are already in phase 1 clinical trials [22], with the aim of downregulating PD-L1 expression to restore an effective anti-tumor immune response.”
BackgroundMethodUsing a Stem Cell–Based Signature to Guide Therapeutic Selection in Cancer
Shats, I., Gatza, M. L., Chang, J. T., Mori, S., Wang, J., Rich, J. N., & Nevins, J. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1735 · Cited by 147
Yam, C., Mani, S. A., & Moulder, S. L. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0095 · Cited by 136
Sangaletti, S., Tripodo, C., Santangelo, A., Castioni, N., Portararo, P., Gulino, A., Botti, L., Parenza, M., Cappetti, B., Orlandi, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.075 · Cited by 114 · cited 1×
“the CSC compartments, we examined the tumor-forming ability of the murine SN25A mammary tumor cells [30] sorted according to PD-L1 versus PD-L1 expression (Table 1) within the gate of SCA-1-positive cells, a murine biomarker for CSCs [31] (Supplementary Fig.”
BackgroundSelf-citationMuenst, S., Soysal, S. D., Tzankov, A., & Hoeller, S. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.980235 · Cited by 97
Targeting cancer stem cells in the clinic: Current status and perspectives
Annett, S., & Robson, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.001 · Cited by 70
McCloskey, C. W., Goldberg, R. L., Carter, L. E., Gamwell, L. F., Al-Hujaily, E. M., Collins, O., Macdonald, E. A., Garson, K., Daneshmand, M., Carmona, E., et al. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00053 · Cited by 67
Polónia, A., Pinto, R., Cameselle-Teijeiro, J. F., Schmitt, F. C., & Paredes, J. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203990 · Cited by 54
Emens, L. A., Braiteh, F., Cassier, P. A., Delord, J., Eder, J. P., Shen, X., Xiao, Y., Wang, Y., Hegde, P. S., Chen, D. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-pd1-6 · Cited by 43
Adams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., Molinero, L. L., Zou, W., Liu, B., Waterkamp, D., Funke, R. P., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p2-11-06 · Cited by 35
Ascierto, P. A., Daniele, B., Hammers, H. J., Hirsh, V., Kim, J. W., Licitra, L. F., Nanda, R., & Pignata, S. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1309-2 · Cited by 22
Cartoon filter via adaptive abstraction
Guastella, D. A., & Valenti, C. F. (2016) · Journal of Visual Communication and Image Representation · doi:10.1016/j.jvcir.2016.01.012 · Cited by 18
Sciortino, G., Orlandi, E., Valenti, C., & Tegolo, D. (2016) · Image Analysis & Stereology · doi:10.5566/ias.1352 · Cited by 16
Cited by
PD-1/PD-L1 pathway: current researches in cancer.
Han, Y., Liu, D., & Li, L. (2020) · PubMed Central · Cited by 2,283
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Metadata
- Authors
- Castagnoli, L., Cancila, V., Cordoba-Romero, S. L., Faraci, S., Talarico, G., Belmonte, B., Iorio, M. V., Milani, M., Volpari, T., Chiodoni, C., Hidalgo-Miranda, A., Tagliabue, E., Tripodo, C., Sangaletti, S., Di Nicola, M., & Pupa, S. M.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- University of Palermo (IT)
- Corresponding author
- Pupa, Serenella M.
- ORCID
- Venue
- Oncogene
- Published
- 2019-01-31
- Volume
- 38
- Issue
- 21
- Pages
- 4047-4060
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC6755989
- OpenAlex
- W2911745810
- Cited by
- 184
- References
- 50
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 19 · 2023: 24 · 2022: 23 · 2021: 41 · 2020: 31 · 2019: 20
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Oncogene (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (16918)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- triple-negative breast cancer, PD-L1 expression, Wnt signaling, cancer stem cells, tumor immune evasion, aldehyde dehydrogenase, CD44, mammospheres, Sca-1, PD-1/PD-L1 inhibitors, stemness signature, tumor-infiltrating T cells
- MeSH terms
- Aldehyde Dehydrogenase, Animals, Female, Humans, Mice, Inbred BALB C, Stem Cells, Biomarkers, Tumor, Down-Regulation, Up-Regulation, Hyaluronan Receptors, Cell Line, Tumor, Wnt Signaling Pathway, B7-H1 Antigen, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.